Trial reportBMC anesthesiology2026
Reduced movement-evoked pain with liposomal bupivacaine versus ropivacaine in transversus abdominis plane block for laparoscopic colorectal surgery: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe analgesic efficacy of liposomal bupivacaine (LB) for transversus abdominis plane block (TAPB) in laparoscopic colorectal surgery (LCS) remains controversial. This trial aimed to determine whether LB provides better analgesia and recovery outcomes than ropivacaine for TAPB.
methodsIn this randomized, double-blind trial, 136 patients undergoing LCS were randomly allocated (1:1) to receive bilateral TAPB with either LB (266 mg total, 133 mg per side) or ropivacaine (0.375%, 20 mL per side). The primary outcome was the area under the curve (AUC) of the visual analogue scale (VAS) for movement-evoked pain (MEP) over 72 h. Secondary outcomes included intraoperative remifentanil consumption, the AUC of VAS for pain at rest (PAR), International Pain Outcome Questionnaire (IPOQ) scores, and the incidence of chronic pain.
resultsCompared with ropivacaine, LB significantly reduced AUC of the VAS for MEP (median difference: -20.15; 95% CI: -33.25, -2.35; P = 0.001); intraoperative remifentanil consumption (-59.75 µg; 95% CI: -142.00, -9.50; P = 0.001); sleep disturbance (-0.5; 95% CI: -1.0, 0; P = 0.002) and pain interference with out-of-bed activities (-1; 95% CI: -1, 0; P = 0.014). No significant intergroup differences were observed in the AUC of the VAS for PAR or chronic pain at 3 months.
conclusionsIn LCS patients, liposomal bupivacaine significantly reduces movement-evoked pain, improves intraoperative analgesia, enhances sleep quality, and alleviates pain-related interference with activity within 72 h postoperatively. However, these benefits did not translate into a reduction in pain at rest or the incidence of chronic pain.
trial registrationChinese Clinical Trial Registry, ChiCTR2400082663. Registered on April 3, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.